Concepedia

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

William G. Wierda, Nirav N. Shah, Chan Y. Cheah, David Lewis, Marc Hoffmann, Catherine C. Coombs, Nicole Lamanna, Shuo Ma, Deepa Jagadeesh, Talha Munir,

The Lancet Haematology · 2024 · 31 citations · 21 references

DOI

Concepts

References

21

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington et al. · Journal of Clinical Oncology · 2014 · 5.3K citations · Full text

, , +22

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Jan A. Burger, Alessandra Tedeschi, Paul M. Barr et al. · New England Journal of Medicine · 2015 · 1.5K citations · Full text

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

John C. Byrd, Peter Hillmen, Paolo Ghia et al. · Journal of Clinical Oncology · 2021 · 594 citations · Full text

The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation

Davide Rossi, Valeria Spina, Clara Deambrogi et al. · Blood · 2011 · 374 citations · Full text

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown et al. · New England Journal of Medicine · 2023 · 190 citations · Full text